Pharmafile Logo
Pharmafocus logo
Advanced Search

allergy

Showing 11 posts of 11 posts found.

Roche shares data from phase 3 trial of Xolair as allergy treatment

February 26, 2024
Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy

Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …

News

FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment

May 12, 2023
Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy

US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …

News
nuts-1736520_1920

Camallergy awarded £1.1m government funding for peanut allergy immunotherapy

March 9, 2021
Manufacturing and Production Camallergy, UK, allergy

Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …

News
european_commission_web

European Commission approves EU’s first peanut allergy treatment

December 21, 2020
Sales and Marketing Aimmune, European Commission, allergy

Aimmune Therapeutics today announced that the European Commission (EC) has approved PALFORZIA as the EU’s first-ever treatment of peanut allergy. …

News
conference_peach

The American Academy of Allergy, Asthma and Immunology calls off its 2020 Annual Meeting due to coronavirus concerns

March 10, 2020
Medical Communications, Research and Development Big Pharma, allergy, america, asthma, immunology

The American Academy of Allergy, Asthma and Immunology (AAAAI) has called off its 2020 Annual Meeting that was schedule to …

News

FDA knocks back Glenmark’s allergic rhinitis therapy Ryaltris

June 25, 2019
Manufacturing and Production, Sales and Marketing FDA, Glenmark, Ryaltris, US, allergy, pharma

Stocks in Indian pharmaceutical firm Glenmark were sent plummeting to a six-year low after it was confirmed that the FDA …

News
dw-anzcxqaqavhl

FDA approves Beximco’s generic version of MSD’s allergy drug Periactin

April 25, 2019
Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma

Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …

News
peanuts02-lg

Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data

March 26, 2019
Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …

News
shutterstock_212432119

Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure

March 18, 2019
Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure

UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …

News
msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

News

Lane Earl Cox wins allergy blood test account

April 16, 2010
Medical Communications LEC, Phadia, allergy

Healthcare advertising agency Lane Earl & Cox has won the account to promote an allergy blood test product from diagnostics …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024